Pentoxifylline improves reoxygenation-induced contractile recovery through a nitric oxide-dependent mechanism in rat papillary muscles

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 4, 2006, Pages 571-577

  Ebrahimi, Farzad ^a   Hajrasouliha, Amir Reza ^a   Tavakoli, Sina ^a   Sadeghipour, Hamed ^a   Ghasemi, Mehdi ^a   Rofoui, Bahareh Rahimzadeh ^a   Ahmadi, Seyed Hossein ^b   Dehpour, Ahmad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Contractility; Hypoxia reoxygenation; Nitric oxide; Pentoxifylline

Indexed keywords

ARGON; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARBON DIOXIDE; ISOPRENALINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; OXYGEN; PENTOXIFYLLINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART PAPILLARY MUSCLE; HYPOXIA; MALE; MUSCLE CONTRACTILITY; NONHUMAN; PRIORITY JOURNAL; RAT; REOXYGENATION;

ADRENERGIC BETA-AGONISTS; ANIMALS; ANOXIA; ENZYME INHIBITORS; ISOPROTERENOL; MALE; MYOCARDIAL CONTRACTION; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PAPILLARY MUSCLES; PENTOXIFYLLINE; RATS; RATS, SPRAGUE-DAWLEY; VASODILATOR AGENTS;

EID: 33748169639     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000211733.53798.d3     Document Type: Article

References (27)

1. Argel MI, Vittone L, Grassi AO, et al. Effect of phosphodiesterase inhibitors on heart contractile behavior, protein kinase activity and cyclic nucleotide levels. J Mol Cell Cardiol. 1980;12:939-954.
2. Vittone L, Chiappe LE, Argel MI, et al. The mechanical and biochemical effects of pentoxifylline on the perfused rat heart. Experientia. 1980;36:1088-1090.
3. Watanabe H, Furukawa Y, Chiba S. Cardiovascular effects of aminophylline and pentoxifylline on intact dogs and isolated dog atria. Jpn Heart J. 1982;23:235-243.
4. Campbell CA, Clavenna CF, Wynne J, et al. Pentoxifylline does not reduce infarct size in a canine model of acute myocardial infarction. Br J Pharmacol. 1988;93:587-590.
5. Bhat VB, Madyastha KM. Antioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs pentoxifylline and lisofylline. Biochem Biophys Res Commun. 2001;288:1212-1217.
6. Horvath B, Marton Z, Halmosi R, et al. In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine. Clin Neuropharmacol. 2002;25:37-42.
7. Berkenboom G, Fang ZY, Unger P, et al. Endothelium-dependent effects of pentoxifylline in rat aorta. Eur J Pharmacol. 1991;193:81-86.
8. Hansen PR. In vitro studies on responses to pentoxifylline and aminophylline of rat mesenteric resistance vessels. Eur J Pharmacol. 1994;261:105-110.
9. Wang P, Ba ZF, Stepp KJ, et al. Pentoxifylline attenuates the depressed endothelial cell function and vascular muscle contractility following trauma and hemorrhagic shock. J Trauma. 1995;39:121-126.
10. Kwiecien S, Brzozowski T, Konturek PC, et al. Gastroprotection by pentoxyfilline against stress-induced gastric damage. Role of lipid peroxidation, antioxidizing enzymes and proinflammatory cytokines. J Physiol Pharmacol. 2004;55:337-355.
11. Nandi JS, Nair KG, Deo S. Inhibition cAMP-phosphodiesterase in the rat heart by pentoxifylline: a new xanthine derivative. Adv Myocardiol. 1980;1:359-365.
12. Hansen PR, Stawski G. Neutrophil mediated damage to isolated myocytes after anoxia and reoxygenation. Cardiovasc Res 1994;28:565-569.
13. Horton JW, White DJ. Free radical scavengers prevent intestinal ischemia-reperfusion-mediated cardiac dysfunction. J Surg Res. 1993;55:282-289.
14. Pridjian AK, Bove EL, Bolling SF, et al. Developmental differences in myocardial protection in response to 5′-nucleotidase inhibition. J Thorac Cardiovasc Surg. 1994;107:520-526.
15. Ulus AT, Aksoyek A, Katircioglu SF, et al. Preservation of myocardial functions by pentoxyphylline cardioplegia during and after cardiopulmonary bypass. Panminerva Med. 2000;42:253-256.
16. Gale SC, Hokama JY, Ritter LS, et al. Pentoxifylline reduces coronary leukocyte accumulation early in reperfusion after cold ischemia. Ann Thorac Surg. 2001;71:1305-1311.
17. Gallenkamper W, Rucker W, Schror K. Cardioprotective actions of pentoxifylline in an animal model of acute myocardial ischaemia. Br J Pharmacol. 1984;81:575-581.
18. Lochner A, Marais E, Genade S, et al. Nitric oxide: a trigger for classic preconditioning? Am J Physiol Heart Circ Physiol. 2000;279:H2752-H2765.
19. Novalija E, Hogg N, Kevin LG, et al. Ischemic preconditioning: triggering role of nitric oxide-derived oxidants in isolated hearts. J Cardiovasc Pharmacol. 2003;42:593-600.
20. Deja MA, Golba KS, Kolowca M, et al. Diazoxide provides protection to human myocardium in vitro that is concentration dependent. Ann Thorac Surg. 2004;77:226 -232.
21. Iwashiro K, Criniti A, Sinatra R, et al. Felodipine protects human atrial muscle from hypoxia reoxygenation dysfunction: a force-frequency relationship study in an in vitro model of stunning. Int J Cardiol. 1997;62:107-132.
22. Monti F, Iwashiro K, Picard S, et al. Adenosine triphosphate-dependent potassium channel modulation and cardioplegia induced protection of human atrial muscle in an in vitro model of myocardial stunning. J Thorac Cardiovasc Surg. 2000;119:842-848.
23. Picard S, Criniti A, Iwashiro K, et al. Protection of human myocardium in vitro by KATP activation with low concentration of bimakalim. J Cardiovasc Pharmacol. 1999;34:162-172.
24. Speechly-Dick ME, Grover GJ, Yellon DM, et al. Does ischemic preconditioning in the human involves protein kinase C and the ATP-dependent K channel? Studies of contractile function after simulated ischemia in an atrial in vitro model. Circ Res. 1995;77:1030-1035.
25. Bell RM, Smith CC, Yellon DM, et al. Nitric oxide as a mediator of delayed pharmacological (A(1) receptor triggered) preconditioning; is eNOS masquerading as iNOS? Cardiovasc Res. 2002;53:405-413.
26. Hattori R, Otani H, Maulik N, et al. Pharmacological preconditioning with resveratrol: role of nitric oxide. Am J Physiol Heart Circ Physiol. 2002;282:H1988-H1995.
27. Geisbuhler TP, Schwager TL, Ervin HD. 3-Isobutyl-1-methylxanthine (IBMX) sensitizes cardiac myocytes to anoxia. Biochem Pharmacol. 2002;63:2055-2062.